Phaseline

Companies › ImmunoGenesis

ImmunoGenesis: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Evofosfamide
Hypoxia-inducible factor 1-alpha (HIF-1α) inhibitor; prodrug activated under hypoxic condi
HIF1APhase 1Metastatic Prostate CancerOct 2027
Zalifrelimab
Cytotoxic T-lymphocyte protein 4 inhibitor
CTLA4Phase 1Metastatic Prostate Cancer; Metastatic Soft Tissue Sarcoma; Diffuse Intrinsic Pontine GliomaOct 2027
IMGS-001–Phase 1Solid TumorDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04028063ZalifrelimabPhase 2Metastatic Soft Tissue SarcomaOncologyApr 2027
NCT04943848ZalifrelimabPhase 1Diffuse Intrinsic Pontine GliomaOncologySep 2027
NCT06782555EvofosfamidePhase 1Metastatic Prostate CancerOncologyOct 2027
NCT06782555ZalifrelimabPhase 1Metastatic Prostate CancerOncologyOct 2027
NCT06014502IMGS-001Phase 1Solid TumorOncologyDec 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

HIF1A (1) CTLA4 (1)

Companies with the same targets

AstraZeneca Innovent Biopharmaceutical Technology (Hangzhou) Kind Pharmaceuticals Sichuan Baili Pharmaceutical Summit Therapeutics Revolution Medicines OncoC4 Bristol-Myers Squibb Akeso InxMed (Shanghai)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.